Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced Intensity Matched Sibling BMT for Sickle Cell Anemia
NCT01877837Phase 3Completed
- Sponsor
- Hackensack Meridian Health
- Start
- Jun 2011
- Primary completion
- Sep 2021
- Modality
- Monoclonal Antibodies, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of alemtuzumab, fludarabine, melphalan in sickle cell disease (SCD), sponsored by Hackensack Meridian Health. Started Jun 2011; status: completed.
02
Drugs
alemtuzumabfludarabinemelphalan
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT01877837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01877837.